Loading...
•
Mar 31, 2022
Amicus Therapeutics Q1 2022 Earnings Report
Amicus Therapeutics announced financial results for Q1 2022, with Galafold revenue growth and progress in regulatory reviews for AT-GAA.
Key Takeaways
Amicus Therapeutics reported Q1 2022 financial results, featuring 18.5% growth in Galafold revenue to $78.7 million. The company is advancing regulatory reviews for AT-GAA in Pompe disease and focusing on financial strength.
Galafold revenue grew by 18.5% to $78.7M in Q1 2022.
A new composition of matter patent for Galafold strengthens U.S. patent protection into 2038.
Amicus is advancing U.S. and EU regulatory reviews and launch preparations for AT-GAA in Pompe disease.
Positive long-term data from a Phase 1/2 study of AT-GAA in Pompe disease was presented at the 2022 MDA Conference.
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics Revenue by Segment
Revenue by Segment
Galafold Revenue
CapyFin.com Forward Guidance
Amicus is focused on ensuring Galafold reaches more patients, securing regulatory approvals for AT-GAA, and maintaining the financial strength of the business.
Positive Outlook
- Continued growth of Galafold.
- Anticipated approval of AT-GAA.
- Strong exclusivity for both Galafold and AT-GAA well into the late 2030s.
- Potential for AT-GAA to become the new global standard of care in Pompe disease.
- Commitment to delivering substantial value for shareholders and patients.
Challenges Ahead
- Tumultuous market conditions.
- Potential delays in regulatory approvals.
- Risks associated with commercializing Galafold and other product candidates.
- Potential for preclinical and clinical studies to be delayed due to safety issues.
- Potential need for additional funding to complete studies and manufacturing.